Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
Blood Cancer Journal, Published online: 16 November 2022; doi:10.1038/s41408-022-00743-0Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 16, 2022 Category: Hematology Authors: Tiziano Barbui Arianna Ghirardi Alessandra Carobbio Arianna Masciulli Greta Carioli Alessandro Rambaldi Maria Chiara Finazzi Marta Bellini Elisa Rumi Daniele Vanni Oscar Borsani Francesco Passamonti Barbara Mora Marco Brociner Paola Guglielmelli Chiara Pa Source Type: research
Breakthrough infections in MPN-COVID vaccinated patients
Blood Cancer Journal, Published online: 15 November 2022; doi:10.1038/s41408-022-00749-8Breakthrough infections in MPN-COVID vaccinated patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 15, 2022 Category: Hematology Authors: Tiziano Barbui Alessandra Carobbio Arianna Ghirardi Alessandra Iurlo Valerio De Stefano Marta Anna Sobas Elisa Rumi Elena Maria Elli Francesca Lunghi Mercedes Gasior Kabat Beatriz Cuevas Paola Guglielmelli Massimiliano Bonifacio Monia Marchetti Alberto Al Source Type: research
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Blood Cancer Journal, Published online: 15 November 2022; doi:10.1038/s41408-022-00748-9Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with other treatment responses (p (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 15, 2022 Category: Hematology Authors: Andrew M. Brunner Alexander Gavralidis Najla Al Ali Anthony Hunter Rami Komrokji Amer Zeidan David A. Sallman Source Type: research
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
Blood Cancer Journal, Published online: 15 November 2022; doi:10.1038/s41408-022-00750-1Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 15, 2022 Category: Hematology Authors: Oliver Van Oekelen Nicole Birrer William Wesson Vincent L. Galate Edward R. Scheffer Cliff Aaron M. Goodman Al-Ola Abdallah Rajshekhar Chakraborty Vinay Prasad Ghulam Rehman Mohyuddin Source Type: research
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
Blood Cancer Journal, Published online: 14 November 2022; doi:10.1038/s41408-022-00751-0In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 14, 2022 Category: Hematology Authors: Monique C. Minnema Joannes F. M. Jacobs Source Type: research
